FDA批准Keytruda治疗高级头颈癌,这是20年来的首次新治疗。 FDA approves Keytruda for advanced head and neck cancer, first new treatment in 20 years.

美国食品和药物管理局批准Keytruda (pembrolizumab) 用于可切除,局部发达的表达PD- L1的头支平状细胞癌 (HNSCC) 的成年患者. The FDA has approved Keytruda (pembrolizumab) for adult patients with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) that expresses PD-L1. 这项批准是在KEYNOTE-689试验的基础上作出的,标志着20多年来当地先进HNSCC首次采用新的治疗办法。 This approval, based on the KEYNOTE-689 trial, marks the first new treatment option for locally advanced HNSCC in over two decades. Keytruda在手术前使用,然后在手术后进行放射治疗,然后继续单独使用。 Keytruda is used before surgery and then with radiation therapy after surgery, followed by continued use alone. 这种治疗旨在改善这类癌症患者的治疗结果。 The treatment aims to improve outcomes for patients with this type of cancer.